- Home
- GLPG vs GDV Comparison
GLPG vs GDV Comparison
Compare GLPG & GDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLPG | GDV |
|---|---|---|
| Founded | 1999 | 2003 |
| Country | Belgium | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.4B |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | GLPG | GDV |
|---|---|---|
| Price | $33.18 | $28.52 |
| Analyst Decision | Hold | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $31.33 | N/A |
| AVG Volume (30 Days) | 101.5K | ★ 186.0K |
| Earning Date | 02-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 5.81% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $336,643,201.00 | N/A |
| Revenue This Year | $1.76 | N/A |
| Revenue Next Year | $0.49 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 10.31 | N/A |
| 52 Week Low | $22.36 | $18.04 |
| 52 Week High | $37.78 | $23.00 |
Technical Indicators
Market Signals| Indicator | GLPG | GDV |
|---|---|---|
| Relative Strength Index (RSI) | 60.18 | 73.30 |
| Support Level | $32.33 | $28.07 |
| Resistance Level | $33.91 | $28.30 |
| Average True Range (ATR) | 0.67 | 0.20 |
| MACD | 0.03 | 0.06 |
| Stochastic Oscillator | 67.51 | 99.99 |
Price Performance
Historical ComparisonAbout GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About GDV Gabelli Dividend & Income Trust of Beneficial Interest
Gabelli Dividend & Income Trust operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of total return on its assets with an emphasis on dividends and income. To achieve its objective, the fund may invest its assets in dividend-paying securities or other income-producing securities. The fund invests in various sectors, in which Financial Services, Food and Beverage, Health Care, Consumer Products, Electronics, and Computer Software & Services and others.